annual CFF:
$25.85M-$144.62M(-84.83%)Summary
- As of today (July 1, 2025), PTGX annual cash flow from financing activities is $25.85 million, with the most recent change of -$144.62 million (-84.83%) on December 31, 2024.
- During the last 3 years, PTGX annual CFF has fallen by -$104.07 million (-80.10%).
- PTGX annual CFF is now -89.56% below its all-time high of $247.63 million, reached on December 31, 2020.
Performance
PTGX Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$11.44M+$7.41M(+183.87%)Summary
- As of today (July 1, 2025), PTGX quarterly cash flow from financing activities is $11.44 million, with the most recent change of +$7.41 million (+183.87%) on March 1, 2025.
- Over the past year, PTGX quarterly CFF has increased by +$4.24 million (+58.95%).
- PTGX quarterly CFF is now -90.99% below its all-time high of $126.98 million, reached on December 31, 2020.
Performance
PTGX quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$30.10M+$4.24M(+16.42%)Summary
- As of today (July 1, 2025), PTGX TTM cash flow from financing activities is $30.10 million, with the most recent change of +$4.24 million (+16.42%) on March 1, 2025.
- Over the past year, PTGX TTM CFF has dropped by -$121.12 million (-80.10%).
- PTGX TTM CFF is now -88.47% below its all-time high of $261.02 million, reached on June 30, 2021.
Performance
PTGX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
PTGX Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -84.8% | +59.0% | -80.1% |
| 3 y3 years | -80.1% | -32.4% | -79.4% |
| 5 y5 years | -43.8% | +2767.9% | -79.7% |
PTGX Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -84.8% | +37.2% | -89.4% | +2071.3% | -82.3% | +59.8% |
| 5 y | 5-year | -89.6% | +37.2% | -91.0% | +2071.3% | -88.5% | +59.8% |
| alltime | all time | -89.6% | +187.2% | -91.0% | +1443.1% | -88.5% | +8460.3% |
PTGX Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $11.44M(+183.9%) | $30.10M(+16.4%) |
| Dec 2024 | $25.85M(-84.8%) | $4.03M(-66.6%) | $25.85M(+15.7%) |
| Sep 2024 | - | $12.05M(+368.5%) | $22.35M(-51.0%) |
| Jun 2024 | - | $2.57M(-64.3%) | $45.61M(-69.8%) |
| Mar 2024 | - | $7.20M(+1266.0%) | $151.21M(-11.3%) |
| Dec 2023 | $170.48M(+805.0%) | $527.00K(-98.5%) | $170.48M(-0.0%) |
| Sep 2023 | - | $35.31M(-67.4%) | $170.50M(+25.5%) |
| Jun 2023 | - | $108.17M(+308.8%) | $135.87M(+378.8%) |
| Mar 2023 | - | $26.46M(+4685.4%) | $28.38M(+50.6%) |
| Dec 2022 | $18.84M(-85.5%) | $553.00K(-18.7%) | $18.84M(-7.9%) |
| Sep 2022 | - | $680.00K(0.0%) | $20.46M(-3.3%) |
| Jun 2022 | - | $680.00K(-96.0%) | $21.16M(-85.5%) |
| Mar 2022 | - | $16.93M(+678.9%) | $145.87M(+12.3%) |
| Dec 2021 | $129.92M(-47.5%) | $2.17M(+57.3%) | $129.92M(-49.0%) |
| Sep 2021 | - | $1.38M(-98.9%) | $254.73M(-2.4%) |
| Jun 2021 | - | $125.39M(>+9900.0%) | $261.02M(+5.2%) |
| Mar 2021 | - | $979.00K(-99.2%) | $248.21M(+0.2%) |
| Dec 2020 | $247.63M(+437.9%) | $126.98M(+1555.8%) | $247.63M(+89.9%) |
| Sep 2020 | - | $7.67M(-93.2%) | $130.42M(-11.9%) |
| Jun 2020 | - | $112.58M(>+9900.0%) | $147.99M(+221.4%) |
| Mar 2020 | - | $399.00K(-95.9%) | $46.05M(+0.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | $46.04M(+90.9%) | $9.78M(-61.3%) | $46.04M(+25.3%) |
| Sep 2019 | - | $25.24M(+137.4%) | $36.74M(+6.4%) |
| Jun 2019 | - | $10.63M(+2625.6%) | $34.53M(+44.0%) |
| Mar 2019 | - | $390.00K(-18.6%) | $23.98M(-0.6%) |
| Dec 2018 | $24.11M(-63.2%) | $479.00K(-97.9%) | $24.11M(-72.8%) |
| Sep 2018 | - | $23.03M(>+9900.0%) | $88.70M(+35.0%) |
| Jun 2018 | - | $74.00K(-86.0%) | $65.70M(-0.0%) |
| Mar 2018 | - | $530.00K(-99.2%) | $65.71M(+0.2%) |
| Dec 2017 | $65.55M(-38.3%) | $65.06M(>+9900.0%) | $65.55M(<-9900.0%) |
| Sep 2017 | - | $31.00K(-64.4%) | -$360.00K(-100.4%) |
| Jun 2017 | - | $87.00K(-76.7%) | $84.89M(+1.0%) |
| Mar 2017 | - | $374.00K(-143.9%) | $84.05M(-20.9%) |
| Dec 2016 | $106.31M(+510.3%) | -$852.00K(-101.0%) | $106.31M(-0.8%) |
| Sep 2016 | - | $85.28M(<-9900.0%) | $107.16M(+173.1%) |
| Jun 2016 | - | -$750.00K(-103.3%) | $39.24M(-2.0%) |
| Mar 2016 | - | $22.63M(>+9900.0%) | $40.05M(+129.9%) |
| Dec 2015 | $17.42M(+93.5%) | $0.00(-100.0%) | $17.42M(0.0%) |
| Sep 2015 | - | $17.36M(>+9900.0%) | $17.42M(>+9900.0%) |
| Jun 2015 | - | $55.00K(+2650.0%) | $57.00K(+2750.0%) |
| Mar 2015 | - | $2000.00 | $2000.00 |
| Dec 2014 | $9.00M | - | - |
FAQ
- What is Protagonist Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Protagonist Therapeutics?
- What is Protagonist Therapeutics annual CFF year-on-year change?
- What is Protagonist Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Protagonist Therapeutics?
- What is Protagonist Therapeutics quarterly CFF year-on-year change?
- What is Protagonist Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Protagonist Therapeutics?
- What is Protagonist Therapeutics TTM CFF year-on-year change?
What is Protagonist Therapeutics annual cash flow from financing activities?
The current annual CFF of PTGX is $25.85M
What is the all time high annual CFF for Protagonist Therapeutics?
Protagonist Therapeutics all-time high annual cash flow from financing activities is $247.63M
What is Protagonist Therapeutics annual CFF year-on-year change?
Over the past year, PTGX annual cash flow from financing activities has changed by -$144.62M (-84.83%)
What is Protagonist Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of PTGX is $11.44M
What is the all time high quarterly CFF for Protagonist Therapeutics?
Protagonist Therapeutics all-time high quarterly cash flow from financing activities is $126.98M
What is Protagonist Therapeutics quarterly CFF year-on-year change?
Over the past year, PTGX quarterly cash flow from financing activities has changed by +$4.24M (+58.95%)
What is Protagonist Therapeutics TTM cash flow from financing activities?
The current TTM CFF of PTGX is $30.10M
What is the all time high TTM CFF for Protagonist Therapeutics?
Protagonist Therapeutics all-time high TTM cash flow from financing activities is $261.02M
What is Protagonist Therapeutics TTM CFF year-on-year change?
Over the past year, PTGX TTM cash flow from financing activities has changed by -$121.12M (-80.10%)